BioSpace News Archive

Aptevo Therapeutics Inc. today announced that the company has been added to the Russell Microcap Index at the conclusion of the 2021 annual reconstitution.

StageZero Life Sciences announced that it will post its Annual and Special Meeting Update Presentation on the Company website on Wednesday, June 30, 2021 at 4:00 p.m. ET.

Explosion of innovation expected with Pharmapack Awards now open for entries.

Celularity today announced expansion of its ongoing Phase 1 clinical trial of CYNK-001 in AML (NCT04310592) to include patients with relapsed/refractory AML (r/r AML) in addition to its ongoing trial in patients with MRD.

Yield10 Bioscience, Inc. today announced two new hires. Tichafa Munyikwa, Ph.D. has been appointed Director of Regulatory Affairs.

Evoke Pharma, Inc. and The International Foundation for Gastrointestinal Disorders (IFFGD), today announced Evoke’s membership into IFFGD’s Industry Council.

Odyssey Group International, Inc. (OTCQB:ODYY) (the “Company” or “Odyssey”), a technology and asset acquisition company focused on developing unique, life-saving medical products today announced the successful completion of their final system safety studies and cellular safety assays for entering clinical trials to treat concussion.

DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, presented new clinical research today at the American Diabetes Association (ADA) 81st Scientific Sessions, the premier diabetes conference for cutting-edge research and advances in diabetes care.

Lyfebulb, and Arena Pharmaceuticals, a company focused on developing innovative therapeutics for immune-mediated conditions, announce the ten patient entrepreneurs selected as finalists for the 2021 Imagining Life Without Limits – An Inflammatory Bowel Disease Innovation Challenge.

CNS Pharmaceuticals today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track Designation for its lead investigational drug, Berubicin, for the treatment of patients with recurrent glioblastoma multiforme (GBM).